A new approach to dose reduction in chronic schizophrenia

Jack Hirschowitz, Robert Hitzemann, Gail Burr, Arlene Schwartz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The bromocriptine growth hormone test (BGHT) was used to monitor D2 receptor activity in a group of 16 chronic schizophrenics who during the baseline phase were receiving ≥20 mg/day haloperidol. In all subjects at baseline, the rise in plasma GH in response to the oral administration of bromocriptine (50 μg/kg) was blocked. The dose of haloperidol was then gradually reduced; the BGHT was repeated as each new dose was established. No escape from blockade of the GH response was observed until the dose of haloperidol was lowered to 10 mg/day (3 of 16 subjects escaped from blockade). At this dose the average plasma haloperidol level was 4 ng/ml. Two additional subjects escaped as the dose was reduced to 5 mg/day and six more escaped as the dose was reduced to 2.5 mg/day. The average haloperidol plasma level at 5 and 2.5 mg/day was 1.6 and 1.2 ng/ml respectively. The remaining five subjects escaped from blockade as the dose was reduced to 0 mg/day. In five subjects, escape from blockade was associated with a significant decrease in positive psychotic symptoms; in these subjects reestablishing the "just" blockade dose of haloperidol did not increase psychotic symptoms. In nine subjects escape from blockade was associated with an increase of positive psychotic symptoms; in six of these patients, reestablishing the "just" blockade dose of haloperidol attenuated psychotic symptoms to near baseline levels. We conclude that the GH challenge test is a useful adjunct to dose-reduction in the chronic patient. Furthermore, for some patients the "just" blockade dose appears to be near the minimum dose with the maximum therapeutic effect.

Original languageEnglish (US)
Pages (from-to)103-113
Number of pages11
JournalNeuropsychopharmacology
Volume5
Issue number2
StatePublished - Sep 1991
Externally publishedYes

Fingerprint

Haloperidol
Schizophrenia
Bromocriptine
Growth Hormone
Therapeutic Uses
Oral Administration

Keywords

  • Bromocriptine
  • Growth hormone
  • Haloperidol
  • Psychoses
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hirschowitz, J., Hitzemann, R., Burr, G., & Schwartz, A. (1991). A new approach to dose reduction in chronic schizophrenia. Neuropsychopharmacology, 5(2), 103-113.

A new approach to dose reduction in chronic schizophrenia. / Hirschowitz, Jack; Hitzemann, Robert; Burr, Gail; Schwartz, Arlene.

In: Neuropsychopharmacology, Vol. 5, No. 2, 09.1991, p. 103-113.

Research output: Contribution to journalArticle

Hirschowitz, J, Hitzemann, R, Burr, G & Schwartz, A 1991, 'A new approach to dose reduction in chronic schizophrenia', Neuropsychopharmacology, vol. 5, no. 2, pp. 103-113.
Hirschowitz, Jack ; Hitzemann, Robert ; Burr, Gail ; Schwartz, Arlene. / A new approach to dose reduction in chronic schizophrenia. In: Neuropsychopharmacology. 1991 ; Vol. 5, No. 2. pp. 103-113.
@article{7ded7b4b454349b5982faae2cca6b394,
title = "A new approach to dose reduction in chronic schizophrenia",
abstract = "The bromocriptine growth hormone test (BGHT) was used to monitor D2 receptor activity in a group of 16 chronic schizophrenics who during the baseline phase were receiving ≥20 mg/day haloperidol. In all subjects at baseline, the rise in plasma GH in response to the oral administration of bromocriptine (50 μg/kg) was blocked. The dose of haloperidol was then gradually reduced; the BGHT was repeated as each new dose was established. No escape from blockade of the GH response was observed until the dose of haloperidol was lowered to 10 mg/day (3 of 16 subjects escaped from blockade). At this dose the average plasma haloperidol level was 4 ng/ml. Two additional subjects escaped as the dose was reduced to 5 mg/day and six more escaped as the dose was reduced to 2.5 mg/day. The average haloperidol plasma level at 5 and 2.5 mg/day was 1.6 and 1.2 ng/ml respectively. The remaining five subjects escaped from blockade as the dose was reduced to 0 mg/day. In five subjects, escape from blockade was associated with a significant decrease in positive psychotic symptoms; in these subjects reestablishing the {"}just{"} blockade dose of haloperidol did not increase psychotic symptoms. In nine subjects escape from blockade was associated with an increase of positive psychotic symptoms; in six of these patients, reestablishing the {"}just{"} blockade dose of haloperidol attenuated psychotic symptoms to near baseline levels. We conclude that the GH challenge test is a useful adjunct to dose-reduction in the chronic patient. Furthermore, for some patients the {"}just{"} blockade dose appears to be near the minimum dose with the maximum therapeutic effect.",
keywords = "Bromocriptine, Growth hormone, Haloperidol, Psychoses, Schizophrenia",
author = "Jack Hirschowitz and Robert Hitzemann and Gail Burr and Arlene Schwartz",
year = "1991",
month = "9",
language = "English (US)",
volume = "5",
pages = "103--113",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A new approach to dose reduction in chronic schizophrenia

AU - Hirschowitz, Jack

AU - Hitzemann, Robert

AU - Burr, Gail

AU - Schwartz, Arlene

PY - 1991/9

Y1 - 1991/9

N2 - The bromocriptine growth hormone test (BGHT) was used to monitor D2 receptor activity in a group of 16 chronic schizophrenics who during the baseline phase were receiving ≥20 mg/day haloperidol. In all subjects at baseline, the rise in plasma GH in response to the oral administration of bromocriptine (50 μg/kg) was blocked. The dose of haloperidol was then gradually reduced; the BGHT was repeated as each new dose was established. No escape from blockade of the GH response was observed until the dose of haloperidol was lowered to 10 mg/day (3 of 16 subjects escaped from blockade). At this dose the average plasma haloperidol level was 4 ng/ml. Two additional subjects escaped as the dose was reduced to 5 mg/day and six more escaped as the dose was reduced to 2.5 mg/day. The average haloperidol plasma level at 5 and 2.5 mg/day was 1.6 and 1.2 ng/ml respectively. The remaining five subjects escaped from blockade as the dose was reduced to 0 mg/day. In five subjects, escape from blockade was associated with a significant decrease in positive psychotic symptoms; in these subjects reestablishing the "just" blockade dose of haloperidol did not increase psychotic symptoms. In nine subjects escape from blockade was associated with an increase of positive psychotic symptoms; in six of these patients, reestablishing the "just" blockade dose of haloperidol attenuated psychotic symptoms to near baseline levels. We conclude that the GH challenge test is a useful adjunct to dose-reduction in the chronic patient. Furthermore, for some patients the "just" blockade dose appears to be near the minimum dose with the maximum therapeutic effect.

AB - The bromocriptine growth hormone test (BGHT) was used to monitor D2 receptor activity in a group of 16 chronic schizophrenics who during the baseline phase were receiving ≥20 mg/day haloperidol. In all subjects at baseline, the rise in plasma GH in response to the oral administration of bromocriptine (50 μg/kg) was blocked. The dose of haloperidol was then gradually reduced; the BGHT was repeated as each new dose was established. No escape from blockade of the GH response was observed until the dose of haloperidol was lowered to 10 mg/day (3 of 16 subjects escaped from blockade). At this dose the average plasma haloperidol level was 4 ng/ml. Two additional subjects escaped as the dose was reduced to 5 mg/day and six more escaped as the dose was reduced to 2.5 mg/day. The average haloperidol plasma level at 5 and 2.5 mg/day was 1.6 and 1.2 ng/ml respectively. The remaining five subjects escaped from blockade as the dose was reduced to 0 mg/day. In five subjects, escape from blockade was associated with a significant decrease in positive psychotic symptoms; in these subjects reestablishing the "just" blockade dose of haloperidol did not increase psychotic symptoms. In nine subjects escape from blockade was associated with an increase of positive psychotic symptoms; in six of these patients, reestablishing the "just" blockade dose of haloperidol attenuated psychotic symptoms to near baseline levels. We conclude that the GH challenge test is a useful adjunct to dose-reduction in the chronic patient. Furthermore, for some patients the "just" blockade dose appears to be near the minimum dose with the maximum therapeutic effect.

KW - Bromocriptine

KW - Growth hormone

KW - Haloperidol

KW - Psychoses

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0025813034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025813034&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 103

EP - 113

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -